SecBot SecBot
Biotech Drug Report Generated Aug 3, 2026

Vraylar

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (marketed)
Time to market
Already on the market, FDA-approved since September 2015 (per local catalyst record). No unapproved Vraylar submission or PDUFA date is verifiable this session.
Why 3/10
No hard, dated binary for Vraylar is verifiable within the next ~12 months: the oral product has been FDA-approved since 2015-09-17 and no Vraylar PDUFA or pivotal readout appears in SecBot's ingested FDA/pipeline data, an approved product with no pending regulatory decision scores 3-5, and at 3 here because it is one product inside a ~$440B mega-cap whose stock historically moves little around FDA events.
Actionable Insight NEUTRAL

Vraylar is an established, marketed revenue contributor inside AbbVie, not a standalone binary catalyst, don't buy the stock expecting a Vraylar-specific event.

Price Chart

Loading chart...

Executive Summary

Vraylar (cariprazine) is an atypical antipsychotic marketed by AbbVie (ABBV, confirmed developer/ticker) and FDA-approved since 2015-09-17 per SecBot's catalyst record, an established product with no pending regulatory binary in the ingested data. The stock-level backdrop is constructive (analyst consensus 22 buy / 9 strong buy / 8 hold / 0 sell; mean price target $270.39 vs. $250.94 last price, ~11.6% implied upside; 12-month return +36.7%).

How It Works

An atypical (second-generation) antipsychotic. Unlike older drugs that fully block dopamine receptors, cariprazine is a "partial agonist", it partially stimulates dopamine D2/D3 and serotonin 5-HT1A receptors, steadying overactive brain signaling linked to schizophrenia and bipolar symptoms while aiming to avoid some of the movement and metabolic side effects of full blockers. This is standard public description of the drug; it could not be re-verified against the FDA label this session due to the web-search outage.

Trial Status

SecBot's local FDA/pipeline data records Vraylar's FDA approval catalyst dated 2015-09-17 (ticker ABBV). No Vraylar-specific FDA actions, new catalyst rows, or Phase 2/3 trial records appear in the last year of ingested data, consistent with a mature marketed drug rather than one in active pivotal development. The long-acting injectable (cariprazine LAI) program could not be confirmed this session because external web verification was unavailable.

The Two-Sided Case

▲ Bull Case4
Established franchise: SecBot's catalyst record confirms Vraylar FDA approval on 2015-09-17 under ABBV, roughly a decade of marketed commercial history in schizophrenia/bipolar space.
Parent-stock backdrop is supportive: analyst consensus on ABBV is 22 buy / 9 strong buy / 8 hold / 0 sell (period 2026-07-01), with mean price target $270.39, median $280, and ~11.6% implied upside vs. the $250.94 last price.
ABBV 13F data shows broad tracked-manager accumulation (adds/doubles in 2025-Q4 through 2026-Q2, e.g., Bridgewater +113.7%, Millennium +3297% shares-change on a small base, Fisher +1347%), a favorable institutional tape around the company, though not Vraylar-specific.
Quant snapshot: ABBV 12-month return +36.67%, 6-month +15.6%, forward P/E 17.77, RSI 51.8, healthy momentum for the parent.
▼ Bear Case4
No near-term binary: no Vraylar PDUFA, pivotal readout, or label decision appears in SecBot's FDA/pipeline data for the past year, approved products don't generate the step-change events traders can date.
Mega-cap dilution: SecBot's local catalyst-outcome data shows ABBV stock averages just -0.47% (1-day) across 5 recorded FDA-approval events; the 2015 Vraylar approval itself predates the local 730-day window, so any Vraylar news would move this ~$440B company modestly at most.
Unverifiable risk overhang: patent-expiry/generic competition and the long-acting injectable (LAI) timeline could not be checked because the external web layer was down all session, treat competitive erosion as an open, unquantified risk.
Mixed stock-level signals: FINRA daily short-volume (execution flow) ran ~55-65% of off-exchange volume on sampled July days, and local 13F data also shows trims/exits at some tracked managers (e.g., Artemis -53.7% in 2026-Q2), though outstanding short interest is small (≈1.28% of est. shares outstanding, 3.45 days to cover, per FINRA semi-monthly data).

Upcoming Catalysts

  • AbbVie quarterly earnings (Q3 2026, roughly late October), Vraylar sales disclosed within the neuroscience segment; the Q2 2026 report (8-K filed 2026-07-31) is the most recent.
  • Any company announcement on the cariprazine long-acting injectable (LAI) development program or regulatory submission, unverifiable this session, watch AbbVie news.
  • Patent/generic litigation developments, flagged as an open risk that could not be confirmed via web this session.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov